Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
| ▸ | GALR3 | O60755 | 2/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.51 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093174 | 0.86 | CFTR (0.61) | DRD2TBXA2RLMNAALOX5APTNF | |
| SCHEMBL22481419 | 0.85 | CYP11B2 (0.50) | DRD2TBXA2RLMNAALOX5APKCNH2 | |
| SCHEMBL29668281 | 0.85 | CYP11B2 (0.50) | DRD2TBXA2RLMNAALOX5APKCNH2 | |
| SCHEMBL8247239 | 0.84 | NOD1 (0.69) | DRD2TBXA2RALOX5APKCNH2SMN1; SMN2 | |
| SCHEMBL22465204 | 0.83 | TBXA2R (0.52) | DRD2TBXA2RALOX5APKMT2AHTT | |
| SCHEMBL20919761 | 0.83 | DRD2 (0.52) | DRD2TBXA2RLMNAALOX5APKCNH2 | |
| SCHEMBL4097969 | 0.83 | NOD1 (0.71) | DRD2TBXA2RLMNAKCNH2TSHR | |
| SCHEMBL1169953 | 0.82 | LMNA (0.70) | DRD2TBXA2RLMNASMN1; SMN2TNF | |
| SCHEMBL20919817 | 0.82 | LMNA (0.52) | DRD2TBXA2RLMNAALOX5APKCNH2 | |
| SCHEMBL22465523 | 0.82 | S1PR1 (0.46) | DRD2TBXA2RLMNAALOX5APKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-7956196-B2 | the major cause of lower respiratory tract illness during infancy and childhood | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-06-07 | — | — | US | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | JANSSEN SCIENCES IRELAND UC (IE) | 2008-06-19 | — | — | US | disclosed |
| EP-1778670-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM Pharma A/S (DK) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006097534-A1 | 1,3-DIHYDRO-BENZIMIDAZOL-2-YLIDENE AMINES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006010446-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 | DRD2 285/4885TBXA2R 3223/4885LMNA 2183/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | DRD2 2913/4885TBXA2R 349/4885LMNA 4022/4885 |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | DRD2 606/4885TBXA2R 451/4885LMNA 2850/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | DRD2 2913/4885TBXA2R 349/4885LMNA 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.